natgillin/translations-raw huggingface dataset:
In men with ED following bilateral nerve-sparing radical prostatectomy, the mean percentage of attempts resulting in successful intercourse was approximately 23% and 26% for the 100 mg and 200 mg avanafil groups, respectively, compared to approximately 9% for placebo.
Pri moških z ED, ki je bila posledica radikalne prostatektomije z ohranjanjem živcev, je bila povprečna stopnja poskusov, ki so se končali z uspešnim spolnim odnosom, približno 23 % oziroma 26 % v skupinah, ki sta prejemali 100 mg oziroma 200 mg avanafila, pri placebu pa je bila stopnja približno 9 %.
In men with either Type 1 or Type 2 diabetes mellitus, the mean percentage of attempts resulting in successful intercourse was approximately 34% and 40% for the 100 mg and 200 mg avanafil groups, respectively, compared to approximately 21% for the placebo group.
Pri moških bodisi s sladkorno boleznijo tipa 1 ali 2 je bila povprečna stopnja poskusov, ki so se končali z uspešnim spolnim odnosom, približno 34 % oziroma 40 % v skupinah, ki sta prejemali 100 mg oziroma 200 mg avanafila, pri placebu pa je bila stopnja približno 21 %.
In men with osteoporosis who took Prolia bone density increased by 5.7 % after one year of treatment compared with a 0.9 % increase in men who took placebo.
Pri moških z osteoporozo, ki so jemali zdravilo Prolia, se je kostna gostota po enem letu zdravljenja povečala za 5,7 % v primerjavi z 0,9-odstotnim povečanjem pri moških, ki so jemali placebo.
in men: temporary low sperm count
pri moških: začasno majhno število semenčic
In MenACWY-TT-038, Nimenrix was demonstrated to be non-inferior to the licensed ACWY-PS vaccine in terms of vaccine response to the four groups (A, C, W-135 and Y) (See Table 8).
V študiji MenACWY-TT-038 se je cepivo Nimenrix izkazalo za neinferiorno odobrenemu cepivu ACWY-PS, kar zadeva odziv na štiri skupine (A, C, W-135 in Y) po cepljenju (glejte preglednico 8).
In metastatic breast cancer, adding Avastin also increased progression-free survival.
Pri metastatskem raku dojke je dodajanje zdravila Avastin prav tako podaljšalo čas preživetja brez napredovanja bolezni.
In metastatic breast cancer, Avastin has been studied in two main studies.
Pri metastatskem raku dojke so zdravilo Avastin proučevali v dveh glavnih študijah.
In metastatic cancer of the colon or rectum, Avastin increased both overall and progression-free survival when it was added to fluoropyrimidine-containing chemotherapy.
Pri metastatskem raku kolona ali danke je zdravilo Avastin, dodano kemoterapiji, ki je vsebovala fluoropirimidin, podaljšalo čas preživetja bolnikov in čas preživetja brez napredovanja bolezni.
In metastatic cancer of the colon or rectum, the effects of adding Avastin to chemotherapy including a fluoropyrimidine have been studied in three main studies.
Pri metastatskem raku kolona ali danke so učinke dodajanja zdravila Avastin h kemoterapiji, ki je vključevala fluoropirimidin, proučevali v treh glavnih študijah.
In metastatic colorectal cancer, Xeloda taken on its own has been compared with the combination of 5- FU and folinic acid in two studies involving 1,207 patients.
Pri metastatski obliki kolorektalnega raka so zdravilo Xeloda, vzeto samostojno, primerjali s kombinacijo 5-FU in folne kisline v okviru dveh študij, ki sta vključevali 1 207 bolnikov.
In metastatic colorectal cancer, Xeloda was as effective as the combination of 5-FU and folinic acid.
Pri metastatskem kolorektalnem raku je bilo zdravilo Xeloda enako učinkovito kot kombinacija 5-FU in folne kisline.
In metastatic gastric cancer, Herceptin given by infusion into a vein in combination with cisplatin and either capecitabine or 5-fluorouracil was compared with the same combination but without Herceptin in one main study involving 594 patients.
Pri metastatskem raku želodca so v eni glavni študiji, v katero je bilo vključenih 594 bolnikov, zdravilo Herceptin, dano v obliki infuzije v veno, v kombinaciji s cisplatinom in bodisi kapecitabinom ali 5- fluorouracilom primerjali z isto kombinacijo, vendar brez dodatka zdravila Herceptin.
In mice dosed subcutaneously with an anti-mouse IL-6 monoclonal antibody, no effects on male or female fertility were observed.
Pri miših, ki so jim subkutano dajali monoklonsko protitelo proti mišjemu IL-6, niso opazili vpliva na plodnost niti pri samcih niti pri samicah.
In mice, a slight reduction in the foetal bodyweight was seen at doses causing maternal toxicity.
Pri miših so pri odmerkih, ki so povzročali toksičnost za mater, ugotovili rahlo zmanjšanje telesne teže plodov.
In mice, a slight reduction in the foetal bodyweight was seen at doses causing maternal toxicity.
Pri miših so ugotovili, da odmerki, ki so toksični za mater, povzročajo nekoliko nižjo telesno maso plodov.
In mice, a slight reduction in the foetal bodyweight was seen at doses causing maternal toxicity.
Pri odmerkih, ki povzročajo maternotoksičnost, je bila pri miših opažena manjša izguba fetalne telesne mase.
In mice, no statistically significant increase in the incidence of tumors was reported at systemic exposures from 7 to 39-times the human exposure (unbound AUC 0-24h measurement) at a dose of 300 mg twice daily.
Pri miših maravirok ni statistično pomembno povečal incidence nobene vrste tumorja pri sistemskih izpostavljenostih v območju od 7- do 39-kratne izpostavljenosti pri človeku (na podlagi merjenja nevezane AUC 0–24h) ob največjem priporočenem odmerku 300 mg dvakrat na dan.
In mid- to late-stage patients experiencing sudden switches between being “ON” and able to move and being “OFF” and having difficulties moving about, Xadago is added to a stable dose of the medicine called levodopa alone or in combination with other medicines for Parkinson’s disease.
»vklopa«, ko je njihovo gibanje normalno, v stanje »izklopa«, ko imajo pri gibanju težave, je zdravilo Xadago dodano stabilnemu odmerku zdravila, imenovanega levodopa, samega ali v kombinaciji z drugimi zdravili za parkinsonovo bolezen.
In mild and moderate hepatically impaired patients (Child-Pugh classification A or B), mean values for sirolimus AUC and t1/2 were increased 61% and 43%, respectively, and CL/F was decreased 33% compared to normal healthy subjects.
Pri bolnikih z blago do zmerno jetrno okvaro (stopnje A ali B po Child-Pughovi klasifikaciji) je bila srednja vrednost AUC povečana za 61 % in t1/2 za 43 %, medtem ko je bila vrednost CL/F zmanjšana za 33 % v primerjavi z vrednostmi pri normalnih zdravih preiskovancih.
In mild cases, symptoms include drowsiness, mental confusion and lethargy, in more serious cases, symptoms may include ataxia, hypotonia, hypotension, respiratory depression, rarely coma and very rarely death.
V blagih primerih simptomi vključujejo dremavost, duševno zmedenost in letargijo, pri težjih primerih pa lahko simptomi vključujejo ataksijo, hipotonijo, hipotenzijo, respiratorno depresijo, redko komo in zelo redko smrt.
In mixed infections in which Gram-negative bacteria are suspected patients should also be treated with an appropriate antibacterial agent(s) against Gram-negative bacteria (see section 5.1).
Pri mešanih okužbah, kjer obstaja sum na Gram-negativne bakterije, se morajo pacienti zdraviti tudi z ustreznim protibakterijskim zdravilom oz. zdravili, proti Gram-negativnim bakterijam (glejte poglavje 5.1).
In mixed infections where Gram negative and/or certain types of anaerobic bacteria are suspected, Cubicin should be co- administered with appropriate antibacterial agent(s).
Pri mešanih okužbah, kjer obstaja sum na prisotnost po Gramu negativnih in/ali določenih tipov anaerobnih bakterij, je treba zdravilo Cubicin dajati skupaj z enim ali več ustreznimi protimikrobnimi zdravili.
In mixed infections where Gram negative and/or certain types of anaerobic bacteria are suspected, oritavancin should be co- administered with appropriate antibacterial agent(s).
Pri mešanih okužbah, kjer obstaja sum na gramnegativne in/ali nekatere vrste anaerobnih bakterij, je treba oritavancin dajati skupaj z drugo ustrezno protibakterijsko učinkovino ali učinkovinami.
In mixed infections where Gram-negative and/or certain types of anaerobic bacteria are suspected, VIBATIV should be co-administered with appropriate antibacterial agent(s).
Pri mešanih okužbah, kjer obstaja sum na gramnegativne in/ali določene vrste anaerobnih bakterij, je treba poleg zdravila VIBATIV dajati tudi druga primerna antibakterijska sredstva.
in mL
v ml
in moderately anaemic adult patients about to undergo major orthopaedic (bone) surgery (for example hip or knee replacement therapy) to reduce the need for blood transfusions.
operacijo dajali lastno kri (predhodno darovanje avtologne krvi). za zmerno slabokrvne bolnike, naročene na večji ortopedski kirurški poseg (poseg na kosteh) (na primer zamenjava kolka ali kolena), da bi zmanjšali potrebo po transfuziji krvi.
in moderately anaemic patients who are going to donate blood prior to surgery, so that their own blood can be given to them during or after surgery (autologous pre-donation).
za zmerno slabokrvne bolnike, ki bodo pred operacijo darovali kri, tako da jim bodo med
In moderately antiretroviral experienced adults, Telzir in combination with low dose ritonavir has not been shown to be as effective as lopinavir / ritonavir.
Pri odraslih bolnikih, ki so bili predhodno zmerno zdravljeni s protiretrovirusnimi zdravili ni bilo dokazano, da bi bilo zdravilo Telzir v kombinaciji z nizkim odmerkom ritonavirja tako učinkovito kot kombinacija lopinavir/ritonavir.
In monkeys dosed orally (50, 150 or 450 mg/kg) for 14 days there was dose-related emesis.
Pri opicah so pri 14-dnevnem peroralnem dajanju (50, 150 ali 450 mg/kg) opazili od odmerka odvisen pojav bruhanja.
In monkeys, administration of DuoTrav twice–daily was shown to induce increased palpebral fissure and to increase iris pigmentation similar to that observed with ocular administration of prostanoids.
Pri opicah so pokazali, da dajanje zdravila DuoTrav dvakrat na dan povzroči povečanje palpebralne fisure in pigmentacije šarenice, podobno kot so opazili pri okularni uporabi prostanoidov.
In monotherapy studies with axitinib (N = 672) for the treatment of patients with RCC, cardiac failure events (including cardiac failure, cardiac failure congestive, cardiopulmonary failure, left ventricular dysfunction, ejection fraction decreased, and right ventricular failure) were reported in 1.8% patients receiving axitinib.
V študijah, v katerih so aksitinib uporabljali kot samostojno zdravilo (n = 672) za zdravljenje bolnikov z RCC, so o dogodkih srčnega popuščanja (vključno s srčnim popuščanjem, kongestivnim srčnim popuščanjem, kardiopulmonalno odpovedjo, disfunkcijo levega prekata, zmanjšanim iztisnim deležem in popuščanjem desnega prekata) poročali pri 1,8 % bolnikov, ki so prejemali aksitinib.
In monotherapy studies with axitinib (N = 850), arterial embolic and thrombotic adverse reactions (including transient ischemic attack, myocardial infarction, and cerebrovascular accident) were reported in 5.3% of patients receiving axitinib.
V študijah, v katerih so aksitinib uporabljali kot samostojno zdravilo (n = 850), so o arterijskih emboličnih in trombotičnih neželenih učinkih (vključno s prehodno možgansko ishemijo, miokardnim infarktom in cerebrovaskularnim insultom) poročali pri 5,3 % bolnikov, ki so prejemali aksitinib.
In monotherapy studies with axitinib (N = 850), haemoptysis was reported in 3.9% of patients; Grade > 3 haemoptysis was reported in 0.5% of patients.
V študijah, v katerih so aksitinib uporabljali kot samostojno zdravilo (n = 850), so o hemoptizi poročali pri 3,9 % bolnikov; o hemoptizi 3. ali višje stopnje so poročali pri 0,5 % bolnikov.
In monotherapy with valsartan, no interactions of clinical significance have been found with the following substances: cimetidine, warfarin, furosemide, digoxin, atenolol, indomethacin, hydrochlorothiazide, amlodipine, glibenclamide.
Med monoterapijo z valsartanom niso ugotovili klinično pomembnih interakcij z naslednjimi učinkovinami: cimetidinom, varfarinom, furosemidom, digoksinom, atenololom, indometacinom, hidroklorotiazidom, amlodipinom, glibenklamidom.
In monotherapy, some patients who experience a decrease in their response may benefit from an increase in dose intensity to 40 mg adalimumab every week.
Med monoterapijo lahko nekaterim bolnikom, ki se jim odziv na Trudexo zmanjša, koristi zvečanje odmerka adalimumaba na 40 mg vsak teden.
In monotherapy, some patients who experience a decrease in their response may benefit from an increase in dose intensity to 40 mg adalimumab every week.
Med monoterapijo lahko nekaterim bolnikom, ki se jim odziv na zdravilo Humira zmanjša, koristi zvečanje odmerka adalimumaba na 40 mg vsak teden.
In more severe cases this may lead to enlargement of the ovaries, collection of fluid in the abdomen and/or chest (which may cause sudden weight gain due to fluid buildup) or clots in the blood vessels.
V hujših primerih lahko vodi do povečanja jajčnikov, kopičenja tekočine v trebuhu in/ali prsni votlini (kar lahko povzroči nenadno povečanje telesne teže) ali nastanka krvnih strdkov v žilah.
In most cases a raised serum calcium level can be reduced to the normal range within 7 days.
V večini primerov lahko zvišane koncentracije kalcija v serumu znižamo na normalno vrednost v dneh.
In most cases it is mild and short lived without requiring treatment.
V večini primerov je bruhanje blago in kratkotrajno ter ga ni bilo potrebno zdraviti.
In most cases no specific treatment is required and the symptoms disappear after a short time (couple of hours or days).
V večini primerov ni potrebno nikakršno specifično zdravljenje in simptomi v kratkem (čez nekaj ur ali dni).
In most cases no specific treatment was required and the symptoms subsided after a couple of hours/days.
V večini primerov posebno zdravljenje ni potrebno, simptomi izginejo po nekaj urah ali dneh.
In most cases of overdose, people have not reported any side effects.
V večini primerov, ko je prišlo do prevelikega odmerjanja, ljudje niso poročali o kakršnihkoli neželenih učinkih.
In most cases of severe liver injury, liver dysfunction had an onset within the first 2 months of therapy, and was characterized by a hepatocellular pattern of injury with transaminase elevations >20xULN, followed by bilirubin increase.
V večini primerov hude okvare jeter, se je moteno delovanje jeter pojavilo v prvih dveh mesecih zdravljenja, in je bila zanj značilna poškodba jetrnih celic s povečanimi vrednostmi transaminaz
In most cases the liver enzyme activities either stabilised or decreased with continued treatment.
V večini primerov ni bilo prisotnih kliničnih znakov, z nadaljevanjem zdravljenja se je aktivnost jetrnih encimov stabilizirala ali zmanjšala.
In most cases, a 10-day treatment course will be sufficient.
Večinoma zadošča 10-dnevno zdravljenje.
In most cases, blood clot formation was detected using scans of the veins or by looking for signs of blood clots in the lungs.
V večini primerov so nastanek krvnih strdkov ugotavljali s slikanjem ven ali preverjanjem znakov krvnih strdkov v pljučih.
In most cases, initial signs and symptoms related to this reaction have appeared within 1 hour following injection, and in all cases full recovery was reported to have occurred within 24 – 72 hours after injection.
V večini primerov so se začetni znaki in simptomi, povezani s tem učinkom, pojavili v 1 uri po injiciranju in v vseh primerih so poročali o popolnem okrevanju v 24 - 72 urah po injiciranju.
In most cases, Nordimet is used for long-term treatment.
V večini primerov se zdravilo Nordimet uporablja za dolgotrajno zdravljenje.
In most cases, PREZISTA can be combined with anti-HIV medicines belonging to another class [e.g.
Večinoma se zdravilo PREZISTA lahko uporablja skupaj z drugimi zdravili proti HIV, ki spadajo v druge skupine [npr.
In most cases, risk factors have been identified, such as pre-existing renal insufficiency, diabetes mellitus, hypovolaemia, overweight, concomitant nephrotoxic medicinal products or age over 65.
V večini primerov so ugotovili dejavnike tveganja, kot so predhodno obstoječa ledvična insuficienca, sladkorna bolezen, hipovolemija, čezmerna telesna masa, sočasno zdravljenje z nefrotoksičnimi zdravili ali starost nad 65 let.
In most cases, risk factors have been identified, such as pre-existing renal insufficiency, diabetes mellitus, hypovolemia, overweight, concomitant nephrotoxic medicinal products, age over 65, sepsis, hyperviscosity or paraproteinemia.
V večini primerov so ugotovili dejavnike tveganja, kot so obstoječa ledvična insuficienca, sladkorna bolezen, hipovolemija, čezmerna telesna masa, sočasna uporaba nefrotoksičnih zdravil, starost nad 65 let, sepsa, hiperviskoznost in paraproteinemija.
In most cases, the infusion can be resumed at a 50 % reduction in rate (e.g. from 100 mg/h to 50 mg/h) when symptoms have completely resolved.
Ko se simptomi popolnoma izboljšajo, lahko pri večini primerov infuzijo nadaljujemo s polovično hitrostjo infundiranja (npr. s 100 mg/h na 50 mg/h).
In most clinical studies afamelanotide plasma levels were below the limit of quantitation by Day 10.
V večini kliničnih študij so bile ravni afamelanotida v plazmi do 10. dneva pod mejo kvantifikacije.
In most clinical trials of Avastin, patients with pre-existing CHF of NYHA (New York Heart Association) II-IV were excluded, therefore, no information is available on the risk of CHF in this population.
V večino kliničnih preskušanj z zdravilom Avastin bolniki, ki so imeli kongestivno srčno popuščanje pred pričetkom zdravljenja (NYHA – New York Heart Association IIIV), niso bili vključeni, zato informacije o tveganju za kongestivno srčno popuščanje pri tej populaciji niso na voljo.
In most clinical trials, patients with recent myocardial infarction, uncompensated congestive heart failure (NYHA III-IV), or uncontrolled hypertension were excluded.
Iz večine kliničnih preskušanj so bili izključeni bolniki z nedavnim srčnim infarktom, dekompenziranim kongestivnim srčnim popuščanjem (NYHA III–IV) ali neurejeno hipertenzijo.
In most clinical trials, patients with recent myocardial infarction, uncompensated congestive heart failure (NYHA III-IV), or uncontrolled hypertension were excluded.
V večini kliničnih preskušanj so bili bolniki z nedavnim srčnim infarktom, dekompenziranim kongestivnim srčnim popuščanjem (NYHA III–IV) ali neurejeno hipertenzijo izključeni.
In most clinical trials, reduced total plasma triglycerides and free fatty acids, and increased HDL- cholesterol levels were observed as compared to placebo, with small, but not clinically significant increases in LDL-cholesterol levels.
V večini kliničnih preskušanj so opažali znižane skupne plazemske koncentracije trigliceridov in prostih maščobnih kislin ter povišane ravni HDL holesterola v primerjavi s placebom, z majhnimi, vendar ne klinično pomembnimi povišanji ravni LDL holesterola.
In most clinical trials, reduced total plasma triglycerides and free fatty acids, and increased HDL- cholesterol levels were observed as compared to placebo, with small, but not clinically significant increases in LDL-cholesterol levels.
V večini kliničnih preskušanj so opažali znižane skupne plazemske koncentracije trigliceridov in prostih maščobnih kislin ter povišane ravni HDL holesterola v primerjavi s placebom, z majhnimi, vendar ne klinično značilnimi povišanji ravni LDL holesterola.
In most clinical trials, reduced total plasma triglycerides and free fatty acids, and increased HDL-cholesterol levels were observed as compared to placebo, with small, but not clinically significant increases in LDL- cholesterol levels.
V večini kliničnih preskušanj so opažali znižane skupne plazemske koncentracije trigliceridov in prostih maščobnih kislin ter povišane ravni HDL holesterola v primerjavi s placebom, z majhnimi, vendar ne klinično značilnimi povišanji ravni LDL holesterola.
In most fistulising Crohn’s disease patients, infliximab was detected in serum for 12 weeks (range 4-28 weeks) after administration of the regimen.
Pri večini bolnikov s Crohnovo boleznijo s fistulami so infliksimab ugotavljali v serumu še 12 tednov (razpon: od 4 do 28 tednov) po infuziji.
In most of the publications the maintenance dose varied between 600 mg/day and 800 mg/day;
V večini publikacij je bil vzdrževalni odmerek od 600 mg/dan do 800 mg/dan.
In most of the studies, the main measure of effectiveness was the amount of virus in the blood before and after six months or a year of treatment, and at ‘follow-up’, six months later.
V večini študij je bilo glavno merilo učinkovitosti delež virusa v krvi pred zdravljenjem, po šestih mesecih ali enem letu zdravljenja ter ob kontrolnem pregledu šest mesecev pozneje.
In most of these studies, Docetaxel Winthrop was combined with other anticancer treatments and compared either with combinations of different treatments or with the same treatments but without Docetaxel Winthrop.
V večini teh študij so zdravilo Docetaxel Winthrop kombinirali z drugimi oblikami zdravljenja proti raku in ga primerjali bodisi s kombinacijami različnih oblik zdravljenja ali enakimi oblikami zdravljenja, vendar brez zdravila Docetaxel Winthrop.
In most of these studies, Taxotere was combined with other anticancer treatments and compared either with combinations of different treatments or with the same treatments but without Taxotere.
V večini teh študij so zdravilo Taxotere kombinirali z drugimi oblikami zdravljenja proti raku in ga primerjali bodisi s kombinacijami različnih oblik zdravljenja ali enakimi oblikami zdravljenja, vendar brez zdravila Taxotere.
In most patients an up to 2.5-fold increase of basic ALA plasma concentrations was observed during the first 3 hours after Ameluz application, which is still within the normal range of previously reported and published endogenous ALA concentrations.
Pri večini bolnikov so opazili do 2,5-kratno povečanje osnovnih koncentracij ALA v plazmi v prvih 3 urah po nanosu zdravila Ameluz, kar je še vedno v normalnem razponu predhodno poročanih in objavljenih endogenih koncentracij ALA.
In most patients arterial blood pressure was well controlled at baseline.
ob izhodišču urejen krvni tlak.
In most patients treatment can be resumed after all symptoms have resolved, without recurrence.
Pri večini bolnikov lahko kemoterapijo z zdravilom Caelyx nadaljujete po pomiritvi vseh simptomov in se ti kasneje več ne bodo ponovili.
In most patients who had a response, there was no evidence of cancer cells left.
Pri večini bolnikov, ki so se na zdravljenje odzvali, ni bilo znakov preostalih rakavih celic.
In most patients with severe hypercalcaemia (albumin-corrected serum calcium*
Pri večini bolnikov s hudo hiperkalciemijo (korigirani kalcij v serumu *  3 mmol/l ali
In most patients with severe hypercalcaemia (albumin-corrected serum calcium* ≥3 mmol/l or ≥12 mg/dl) 4 mg is an adequate single dose.
Pri večini bolnikov s hudo hiperkalciemijo (korigirani kalcij v serumu* ≥ 3 mmol/l ali ≥ 12 mg/dl) zadošča enkratni odmerek 4 mg.
In most patients, after administration of a single oral dose, onset of antihypertensive activity occurs within 2 hours, and the peak drop in blood pressure is achieved within 4–6 hours.
Pri večini bolnikov se antihipertenzivni učinek pojavi v 2 urah po aplikaciji posamičnega peroralnega odmerka, največji padec krvnega tlaka pa je dosežen v 4 do 6 urah.
In most patients, infliximab could be detected in the serum for at least 8 weeks after the recommended single dose of 5 mg/kg for Crohn’s disease and the rheumatoid arthritis maintenance dose of 3 mg/kg every 8 weeks.
Pri večini bolnikov so infliksimab našli v serumu še najmanj 8 tednov po priporočenem enkratnem odmerku za zdravljenje Crohnove bolezni, 5 mg/kg, ali pri vzdrževalnem odmerku za zdravljenje revmatoidnega artritisa, 3 mg/kg na vsakih 8 tednov.
In most PNH patients, eculizumab serum concentrations of approximately 35 microgram/ml are sufficient for essentially complete inhibition of terminal complement-mediated intravascular haemolysis.
Pri večini bolnikov s PNH serumske koncentracije ekulizumaba približno 35 mikrogramov/ml zadoščajo za praktično popolno zavrtje intravaskularne hemolize, posredovane s terminalnim komplementom.